Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
US Army
Cipla
Baxter

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,254,308

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,254,308
Title:Kits and methods for the treatment of cancer using gliadin peptides
Abstract: Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition comprising a gliadin peptide and instructions for administering the peptide to a patient. The kit may further comprise a pharmaceutical composition comprising at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor and instructions for co-administering the compounds. A method of treating cancer according to the invention comprises administering a gliadin peptide to a patient and may further comprise co-administering at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor. Co-administration of a gliadin peptide and receptor tyrosine kinase inhibitor to a patient with cancer is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor.
Inventor(s): Shaw; Fred L. (Inverness, IL)
Assignee: BARMARSA RESEARCH LLC (Inverness, IL)
Application Number:14/200,585
Patent Claims:1. A method of treating cancer comprising administering a therapeutically effective amount of a gliadin peptide to a patient with cancer, wherein the gliadin peptide comprises the amino acid sequence set forth in SEQ ID NO:1 and is administered in a composition that does not contain an additional chemotherapeutic agent, wherein the cancer is non-small cell lung cancer.

2. The method of claim 1, further comprising co-administering a therapeutically effective amount of at least one chemotherapeutic agent.

3. The method of claim 2, wherein the at least one chemotherapeutic agent is a receptor tyrosine kinase inhibitor.

4. The method of claim 1, wherein the gliadin peptide is an alpha-gliadin peptide selected from the group consisting of alpha-gliadin peptide p31-55, p31-49, and derivatives and fragments thereof.

5. The method of claim 3, wherein the receptor tyrosine kinase inhibitor is an epidermal growth factor receptor (EGFR) inhibitor.

6. The method of claim 5, wherein the EGFR inhibitor is gefitinib.

7. The method of claim 5, wherein the EGFR inhibitor is erlotinib.

8. The method of claim 3, wherein co-administering the gliadin peptide and receptor tyrosine kinase inhibitor is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor.

9. The method of claim 1, wherein the patient is human.

10. The method of claim 5, wherein the patient does not have mutations in the EGFR gene known to increase sensitivity to EGFR inhibitors.

11. The method of claim 2, wherein co-administering the gliadin peptide and at least one chemotherapeutic agent is effective to decrease or prevent resistance of the cancer to the chemotherapeutic agent.

12. The method of claim 2, wherein co-administering the gliadin peptide and at least one chemotherapeutic agent is effective to increase the efficacy of the chemotherapeutic agent.

13. The method of claim 11, wherein the chemotherapeutic agent is administered first.

14. The method of claim 11, wherein the chemotherapeutic agent is selected from the group consisting of azacitidine, axathioprine, bevacizumab, bleomycin, capecitabine, carboplatin, chlorabucil, cisplatin, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, etoposide, fluorouracil, gemcitabine, trastuzumab, idarubicin, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, tafluposide, teniposide, tioguanine, retinoic acid, valrubicin, vinblastine, vincristine, vindesine, vinorelbine, and combinations thereof.

15. The method of claim 2, comprising administering the gliadin peptide via a route selected from the group consisting of oral, intramuscular, intravenous, respiratory/inhalation, and subcutaneous.

Details for Patent 9,254,308

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up BARMARSA RESEARCH LLC (Inverness, IL) 2033-03-07 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up BARMARSA RESEARCH LLC (Inverness, IL) 2033-03-07 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up BARMARSA RESEARCH LLC (Inverness, IL) 2033-03-07 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Covington
Deloitte
Fish and Richardson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.